Clinical impact of central nervous system‐directed therapies on intravascular large B‐cell lymphoma: A single institution's experience

Intravascular large B‐cell lymphoma (IVLBCL) is a rare subtype of B‐cell lymphoma characterized by aggressive disease progression with a high incidence of central nervous system (CNS) involvement. We retrospectively analyzed 16 patients with de novo IVLBCL treated at our hospital between 2004 and 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Takahashi, Hiromichi, Nishimaki, Haruna, Nakanishi, Yoko, Hamada, Takashi, Nakagawa, Masaru, Iizuka, Kazuhide, Uchino, Yoshihito, Iriyama, Noriyoshi, Miura, Katsuhiro, Nakayama, Tomohiro, Masuda, Shinobu, Hatta, Yoshihiro, Nakamura, Hideki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9176124/
https://www.ncbi.nlm.nih.gov/pubmed/35846032
http://dx.doi.org/10.1002/jha2.380
Descripción
Sumario:Intravascular large B‐cell lymphoma (IVLBCL) is a rare subtype of B‐cell lymphoma characterized by aggressive disease progression with a high incidence of central nervous system (CNS) involvement. We retrospectively analyzed 16 patients with de novo IVLBCL treated at our hospital between 2004 and 2018 with either standard therapy plus CNS‐directed therapy or standard therapy alone. CNS‐directed therapy was associated with a significantly better 2‐year CNS‐free survival (100% vs. 63%, p = 0.0191), despite no significant effects on progression‐free or overall survival. Further studies should assess CNS‐focused treatment in patients with IVLBCL with or without primary CNS involvement.

Ejemplares similares